American Trust Buys Shares of 580 Medpace Holdings, Inc. (NASDAQ:MEDP)

American Trust bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 1st quarter, Holdings Channel.com reports. The firm bought 580 shares of the company’s stock, valued at approximately $234,000.

Several other institutional investors have also recently bought and sold shares of MEDP. Rise Advisors LLC bought a new stake in shares of Medpace during the 1st quarter worth approximately $27,000. Mather Group LLC. bought a new stake in shares of Medpace during the 1st quarter worth approximately $28,000. Fidelis Capital Partners LLC bought a new stake in shares of Medpace during the 1st quarter worth approximately $31,000. Arcadia Investment Management Corp MI raised its stake in shares of Medpace by 40.3% during the 1st quarter. Arcadia Investment Management Corp MI now owns 101 shares of the company’s stock worth $41,000 after purchasing an additional 29 shares in the last quarter. Finally, J.Safra Asset Management Corp raised its stake in shares of Medpace by 87.0% during the 1st quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock worth $41,000 after purchasing an additional 47 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

NASDAQ MEDP traded down $8.16 on Friday, reaching $377.00. The stock had a trading volume of 322,082 shares, compared to its average volume of 337,243. The firm has a fifty day moving average of $403.18 and a two-hundred day moving average of $386.08. Medpace Holdings, Inc. has a 1-year low of $227.21 and a 1-year high of $459.77. The company has a market cap of $11.69 billion, a P/E ratio of 38.43, a price-to-earnings-growth ratio of 2.00 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, July 22nd. The company reported $2.75 EPS for the quarter, beating analysts’ consensus estimates of $2.54 by $0.21. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The firm had revenue of $528.10 million for the quarter, compared to analyst estimates of $528.41 million. During the same period in the prior year, the firm posted $1.93 EPS. The company’s revenue for the quarter was up 14.6% on a year-over-year basis. Research analysts predict that Medpace Holdings, Inc. will post 11.66 EPS for the current fiscal year.

Insider Transactions at Medpace

In other news, Director Ashley M. Keating 1,300 shares of Medpace stock in a transaction on Tuesday, July 30th. The was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Ashley M. Keating 1,300 shares of Medpace stock in a transaction on Tuesday, July 30th. The was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO August J. Troendle sold 3,987 shares of the stock in a transaction on Friday, May 24th. The stock was sold at an average price of $395.22, for a total value of $1,575,742.14. Following the sale, the chief executive officer now directly owns 660,351 shares in the company, valued at $260,983,922.22. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,519 shares of company stock valued at $5,765,631. 20.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Truist Financial assumed coverage on Medpace in a research note on Thursday. They set a “hold” rating and a $415.00 price objective on the stock. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and upped their price objective for the stock from $340.00 to $450.00 in a research note on Tuesday, April 23rd. StockNews.com upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Thursday. Mizuho started coverage on Medpace in a report on Tuesday, May 28th. They set a “buy” rating and a $435.00 target price on the stock. Finally, Robert W. Baird decreased their target price on Medpace from $469.00 to $430.00 and set an “outperform” rating on the stock in a report on Wednesday, July 24th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $423.00.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.